Soligenix granted patent for IBS treatment

PRINCETON, N.J. Soligenix has obtained a patent for a drug to treat irritable bowel syndrome, the drug maker said Wednesday.

The company said the U.S. Patent Office issued U.S. Patent No. 7,704,985, covering the use of beclomethasone dipropionate as a treatment for IBS and related diseases.

“There is an increasing awareness that IBS results in part from an inflammatory cascade in the [gastrointestinal] tract, which makes it amenable to treatment with topically active steroids such as oral BDP,” Soligenix CEO Christopher Schaber said. “This potentially expands the available treatment options for IBS.”

Login or Register to post a comment.